Agree finding new 5HT2A ligands is cool, what would be truly interesting is having a suite of totally selective ligands for the entire 5-HT receptor family.
I feel like a lot psychopharmacological research into a lot of mental disorder is severely hampered by
1) the complex interactions of the various serotonin receptors(and also with other receptors like D2)
2) the lack of truly selective ligands, necessitating a hodge podge of less selective agonists combined with selective antagonists to isolate the effects of specific receptor interactions(making it hard to do this sort of thing in humans). Or using knockout mice, which is also kind of dubious because you've now made a fundamentally different brain and are trying to compare it to a normal one. And that's sort of hit and miss.
And as the article says, >"There were a lot of models that we didn’t even try because we thought they were so bad,...”
With all the associated bullshit and snake oil and romanticizing of the "good old natty days" too, of course.
Big $$$ industry, at least until our brave future does away with voluntary reproduction altogether, being the reason people bother to exercise in the first place.
I do hope people choose a nice walk over color match games.
The 3d structure of GPCRs is intimately associated with the cell membrane, with one end sticking out into the extracellular environment, and another sticking out into the interior of the cell. Simply getting that sort of protein, which is not soluble in water, was a massive challenge and the first structures didn't arrive until the early 2000s, when people learned how to crystallize GPCRs using detergents and other solvents that simulated cell membranes.
So many diseases are caused by misregulation of signal trandsduction... let's take some examples. Vasopressin is a drug that also happens to be a natural body product. In some diseases, people don't make enough vasopressin to regular the kidneys properly, leading to a form of diabetes, and simply giving people more of it helps reduce the symptoms. I guess in this case (not certain), people have mutations in the GPCR that receives the vasopressin signal that attenuates the signal "too much" and by just dosing the patient with a lot more, more signal gets sent inside the cell.
I think at least 10 nobel prizes in medicine have been awarded for research related to GPCRs, which has uncovered a wide range of medically relevant knowledge of physiology. The NERSC supercomputer "Cori" was named for Gertie Cori, who helped discover some of the core mechanisms in human metabolism during the golden age of metabolic biochemistry.
I think the simplest way to think about it is being able to target specific GPCRs is like being in front of a switchboard with buttons and knobs controlling every critical detail of how human bodies manage and maintain themselves.
What seems more likely to you: that the (obviously worse [1]) structures produced by alphafold are somehow magically capturing protein dynamics, or…the virtual screening method (DOCK) used by the paper is relatively insensitive to the quality of the underlying model? They say right there in the article that neither screen was obviously enriched versus the other (the hit rate was around 50% for both branches, which was essentially the same as for the very different retrospective screening method in the same paper [2]).
I’m putting my money on the parsimonious answer. Running structures through a large enough virtual screen will almost always find something that binds, even if the starting model isn't great.
[1] at least in the case of the x-ray structure. Using a cryoEM structure is sort of interesting, since they’re blurry anyway.
[2] the actual paper: https://www.biorxiv.org/content/10.1101/2023.12.20.572662v1....
I think you're right, that running lots of structures through virtual screens will find lots of binders. In the middle days of protein design (well before AF2), people went from not being able to design anything, to being able to easily design "rocks"- proteins that were exceptionally stable, but didn't do anything interesting. Their loss function that they maximized for was stability. But that comes at a cost: high stability seems to prevent lability (which is useful for enzymes). And I think that if you just pass enough stuff through a good-enough program, you'll find lots of binders, but those binders won't actually be useful binders. We already know from decades of work that we can find lots of nanomolar and picomolar binders that don't do anything worthwhile (or have side effects).
My conclusion is: we may very well be on the tip of solving another bottleneck in the drug discovery pipeline, or, we might just be bumbling around in a big space and found a nice local minimum. I don't think AF2 or similar systems on their own are going to completely solve the problem, and until DeepMind or somebody else creates something that can truly address the hard problems in human biology, the most we can hope for is finding more effective new drugs more cheaply and somehow couple that with improvements in genetic personalization.
It seems weird to give the peace prize to a model. What about the people who made the model, or is that what you mean?
Unsure of the merits of this finding myself, but I'd be cautious given just this past week DeepMind was accused of publishing gibberish by Chemists: https://twitter.com/Robert_Palgrave/status/17443839652705816...
I agree the chemistry paper does not look g ood but it's hard to say yet. Like I've said elsewhere DM and Google Researchers are under huge pressure to make their results look as good as possible. Already people have serious concerns about another Google paper using ML for IC layout.
But the really important conclusion of the paper, which I truly hope bears out, is that AF2 models are useful for finding binders to GPCRs.
GPCRs are one of the largest (if not largest) drug targets and work (including my own) showed that modelling protein dynamics using expensive simulations was likely to be necessary to make accurate predictions of GPCR binding molecules. If this paper is correct, AF2 is actually able to recapitulate much of the detail that we previously believed required expensive dynamics simulations, which is about the best possible news because it suggests that we can omit these costly calculations.
It's almost certain now that AF2 will win the Nobel Prize, as this represents some of the most exciting breakthroughs in the past few decades.